Key Highlights
- Adagene shares fell 12.25% to close at $1.76 on November 13, 2026.
- Enrollment is complete in a Phase 2 trial with 60 randomized patients.
- Initial Phase 2 results are expected in the first half of 2027.
- The company has confirmed Phase 3 plans with the FDA.
Adagene (NASDAQ:ADAG)'s American depositary shares closed Friday, November 13, 2026, at $1.76, down 12.25%. The company published no announcement for the session. Its most recent news was released on Monday, November 9, four days earlier. The decline came on a risk-off day for growth names across the market, in a small-cap biotechnology stock.
Masked Antibody Lead Program
Adagene is a clinical-stage company developing masked antibody therapies using its SAFEbody technology. Its lead program is muzastotug, which it is testing in combination with Merck (NYSE:MRK)'s Keytruda, or pembrolizumab, in microsatellite stable colorectal cancer, a form of the disease that has historically responded poorly to immunotherapy. On November 9, Adagene said it had completed enrollment in a randomized Phase 2 dose-optimization trial of the combination, with 60 patients randomized one-to-one between two dosing arms. Arm A uses 10 mg/kg every three weeks for four doses, followed by 10 mg/kg every six weeks; Arm B uses 20 mg/kg every six weeks for two doses, followed by 15 mg/kg every six weeks.
The primary endpoint of the Phase 2 study is overall response rate, with duration of response, progression-free survival and overall survival as secondary endpoints. Adagene said initial results are expected in the first half of 2027 and will be used to choose the dose regimen for a Phase 3 trial. The company said it has confirmed Phase 3 plans with the FDA: the trial would enroll patients with late-line microsatellite stable colorectal cancer without liver metastases, including those with peritoneal involvement, with overall survival as the primary endpoint and a standard-of-care control arm. Adagene said the FDA did not require a muzastotug monotherapy arm. The company also acknowledged an additional Equity Investment from Sanofi (NASDAQ:SNY) tied to the trial.
Readout Not Due Until 2027
The stock rose on the day of the announcement, but by the end of the week the shares had given ground. With the next meaningful data readout not expected until 2027, the stock lacks a near-term catalyst, which can leave it exposed to broader flows in the meantime.
Those flows were negative for risk assets on Friday. The Nasdaq Composite fell 0.91% to 25,136.27 and the S&P 500 lost 0.40% to 7,561.67, while the Dow Jones Industrial Average rose 0.10%. The selling was led by technology and semiconductor stocks after Nvidia (NASDAQ:NVDA) said on Thursday that chief executive Jensen Huang had resigned, but it spilled into other speculative corners of the market. The Russell 2000 fell 0.31%. Rates were also a factor: October producer prices rose 0.3% month over month, slightly below the 0.4% expected, but were up 6.5% from a year earlier, the largest 12-month rise since November 2022. The 10-year Treasury Yield was about 5.13% early Friday, and futures pricing showed a Fed rate rise in December as close to certain. Higher rates raise the Cost of Capital for cash-consuming biotechs and tend to compress the value placed on distant drug revenue.
Milestones Still Ahead
For Adagene, the milestones that matter remain the first-half 2027 Phase 2 readout and the eventual start of a Phase 3 study. Friday's fall came with no new disclosure, in a thinly traded, low-priced stock on a difficult session for growth and biotech names.






Please wait processing your request...